



2023-24
PUBLICATIONS

April – June 2024:

1. Mwesigwa A, Ocan M, Musinguzi B, Nante RW, Nankabirwa JI, Kiwuwa SM, Kinengyere AA, **Castelnuovo B**, Karamagi C, Obuku EA, Nsobya SL, Mbulaiteye SM, Byakika-Kibwika P. *Plasmodium falciparum genetic diversity and multiplicity of infection based on msp-1, msp-2, glurp and microsatellite genetic markers in sub-Saharan Africa: a systematic review and meta-analysis*. *Malar J*. **2024 Apr 8**;23(1):97. doi: 10.1186/s12936-024-04925-y. PMID: 38589874; PMCID: PMC11000358.
2. **Musubire A**, Kagimu E, Mugabi T, Meya DB, Boulware DR, Bahr NC. *Complex Decisions in HIV-Related Cryptococcosis: Addressing Second Episodes of Cryptococcal Meningitis*. *Curr HIV/AIDS Rep*. **2024 Apr**;21(2):75-85. doi: 10.1007/s11904-024-00691-3. Epub 2024 Feb 24. PMID: 38400871; PMCID: PMC11016006.
3. Thomas D, Nakabugo L, Nambi F, Kibuuka J, Muwonge TR, Feutz E, Thomas KK, Simoni JM, Montgomery ET, Ware N, Wyatt MA, Katz IT, Kadama H, **Mujugira A**, Heffron R; Partners PrEP Program Team. *Intimate Partner Violence and Adherence to PrEP and ART Among Ugandan HIV Serodifferent Couples*. *J Acquir Immune Defic Syndr*. **2024 Apr 1**;95(4):347-354. doi: 10.1097/QAI.0000000000003368. PMID: 38133584; PMCID: PMC10896193.
4. Kebede S, Brazier E, Freeman AM, **Muwonge TR**, Choi JY, de Waal R, Poda A, Cesar C, Munyaneza A, Kasozi C, Pasayan MKU, Althoff KN, Shongo A, Low N, Ekouevi D, Veloso VG, Ross J; International Epidemiology Databases to Evaluate AIDS (IeDEA). *Preexposure prophylaxis availability among health facilities participating in the global International epidemiology Databases to Evaluate AIDS (IeDEA) consortium*. *AIDS*. **2024 Apr 1**;38(5):751-756. doi: 10.1097/QAD.0000000000003824. Epub 2023 Dec 21. PMID: 38133656; PMCID: PMC10939841. **(No PDF)**
5. Michael O, Darshit D, Mary K, Mutekoba U, Timothy M, Francis BX, Denis K, Edward K, Machyo OF, Henry D, William B, **Ponsiano O**. *Advancing complex hepato-pancreato-biliary surgery in Uganda: Challenges and outcomes*. *World J Surg*. **2024 Apr**;48(4):924-931. doi: 10.1002/wjvs.12097. Epub 2024 Feb 7. PMID: 38323680. **(No PDF)**
6. Delphin M, Mohammed KS, Downs LO, Lumley SF, Waddilove E, Okanda D, Aliyan N, Van Schalkwyk M, Anderson M, **Ocamo P**, Maponga T, Torimiro J, Iwuji C, Ndung'u T, Matthews PC, Taljaard J. *Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection*. *Lancet Gastroenterol Hepatol*. **2024 Apr**;9(4):383-392. doi: 10.1016/S2468-1253(23)00315-1. Epub 2024 Feb 15. PMID: 38367632. **(No PDF)**
7. Xie YL, Eichberg C, Hapeela N, Nakabugo E, Anyango I, Arora K, Korte JE, Odero R, van Heerden J, Zemanay W, Kennedy S, Nabeta P, Hanif M, Rodrigues C, Skrahina A, Stevens W, Dietze R, Liu X, Ellner JJ, Alland D, Joloba ML, Schumacher SG, McCarthy KD, **Nakiyingi L**, Dorman SE. *Xpert MTB/RIF Ultra versus mycobacterial growth indicator tube liquid culture for detection of Mycobacterium tuberculosis in symptomatic adults: a diagnostic accuracy study*. *Lancet Microbe*. **2024 Apr 9**:S2666-5247(24)00001-6. doi: 10.1016/S2666-5247(24)00001-6. Epub ahead of print. PMID: 38608680.
8. Musisi E, Wamutu S, Ssengooba W, Kasiinga S, Sessolo A, Sanyu I, Kaswabuli S, Zawedde J, Byanyima P, Kia P, Muwambi W, Toskin DT, Kigozi E, Walbaum N, Dombay E, Legrady MB, Ssemambo KD, Joloba M, Kuchaka D, **Worodria W**, Huang L, Gillespie SH, Sabiiti W. *Accuracy of the tuberculosis molecular bacterial load assay to diagnose and monitor response to anti-tuberculosis therapy: a longitudinal comparative study with standard-of-care smear microscopy, Xpert MTB/RIF Ultra, and culture in Uganda*. *Lancet Microbe*. **2024 Apr**;5(4):e345-e354. doi: 10.1016/S2666-5247(23)00367-1. Epub 2024 Mar 5. PMID: 38458206.
9. van der Wekken-Pas L, Nassiwa S, Malaba T, **Lamorde M**, Myer L, Waitt C, Reynolds H, Khoo S, He N, van Leeuwen L, Burger D, Wang D, Colbers A. *Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV*. *AIDS*. **2024 Jun 1**;38(7):975-981. doi: 10.1097/QAD.0000000000003852. Epub 2024 Mar 6. PMID: 38277390; PMCID: PMC11064908.

10. **Mayito J**, Kibombo D, Olaro C, Nabadda S, Guma C, Nabukenya I, Busuge A, Dhikusooka F, Andema A, Mukobi P, Onyachi N, Watmon B, Obbo S, Yayi A, Elima J, Barigye C, Nyeko FJ, Mugerwa I, Sekamatte M, Bazira J, Walwema R, **Lamorde M**, Kakooza F, Kajumbula H. *Characterization of Antibiotic Resistance in Select Tertiary Hospitals in Uganda: An Evaluation of 2020 to 2023 Routine Surveillance Data*. *Trop Med Infect Dis*. **2024 Apr 5**;9(4):77. doi: 10.3390/tropicalmed9040077. PMID: 38668538; PMCID: PMC11053536.
11. **Nakatudde I**, Katana E, Agnes Odongpiny EL, Nalugga EA, **Castelnuovo B**, Fowler MG, Musoke P. *Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda*. *AIDS Res Ther*. **2024 Apr 18**;21(1):23. doi: 10.1186/s12981-024-00615-6. PMID: 38637785; PMCID: PMC11027216.
12. **Mujugira A**, Karungi B, Mugisha J, Nakyanzi A, Nampewo O, Naddunga F, Kamusiime B, Nsubuga R, Nyanzi KR, Muwonge TR, Wyatt MA, Ware NC, Gandhi M, Haberer JE. *Urine tenofovir testing for real-time PrEP adherence feedback: a qualitative study involving transgender women in Uganda*. *J Int AIDS Soc*. **2024 May**;27(5):e26255. doi: 10.1002/jia2.26255. PMID: 38695107; PMCID: PMC11063774.
13. Zhang M, Tseng AS, Anguzu G, Barnabas RV, Davis JL, **Mujugira A**, Flaxman AD, Ross JM. *Modeled estimates of HIV-serodifferent couples in tuberculosis-affected households in four sub-Saharan African countries*. *PLOS Glob Public Health*. **2024 May 2**;4(5):e0002609. doi: 10.1371/journal.pgph.0002609. PMID: 38696500; PMCID: PMC11065259.
14. Mpirirwe R, Segawa I, Ojiambo KO, Kamacooko O, Nangendo J, Semitala FC, Kyambadde P, Kalyango JN, Kiragga A, Karamagi C, Katahoire A, Kamya M, **Mujugira A**. *HIV pre-exposure prophylaxis uptake, retention and adherence among female sex workers in sub-Saharan Africa: a systematic review*. *BMJ Open*. 2024 Apr 25;14(4):e076545. doi: 10.1136/bmjopen-2023-076545. PMID: 38670600; PMCID: PMC11057315.
15. **Meya DB**, Williamson PR. *Cryptococcal Disease in Diverse Hosts*. *N Engl J Med*. **2024 May 2**;390(17):1597-1610. doi: 10.1056/NEJMra2311057. PMID: 38692293.
16. Wagner GJ, Bogart LM, Matovu JKB, **Okoboi S**, Gwokyalya V, Klein DJ, Ninsiima S, Green HD. *Characteristics of Received HIV Prevention Advocacy from Persons Living with HIV in Uganda, and Associations with HIV Testing and Condom Use Among Social Network Members*. *AIDS Behav*. **2024 Apr 20**. doi: 10.1007/s10461-024-04347-6. Epub ahead of print. PMID: 38642213.
17. Okello M, Srikant S, Darshit D, **Ocama P**. *Outcomes of Proximal Spleno-Renal Shunt Operations for Idiopathic Portal Hypertension in Tertiary Hospital in the Sub-Sahara*. *Int Med Case Rep J*. **2024 Apr 23**;17:381-386. doi: 10.2147/IMCRJ.S453341. PMID: 38681996; PMCID: PMC11055520.
18. **Izudi J**, Bajunirwe F, Cattamanchi A. *Negative effects of undernutrition on sputum smear conversion and treatment success among retreatment cases in Uganda: A quasi-experimental study*. *J Clin Tuberc Other Mycobact Dis*. **2024 Feb 24**;35:100422. doi: 10.1016/j.jctube.2024.100422. PMID: 38434999; PMCID: PMC10907175.
19. Collier SM, **Semeere A**, Chemtai L, Byakwaga H, Lagat C, Laker-Oketta M, Bramante J, Pacheco A, Zehtab M, Strahan AG, Grant M, Bogart LM, Bassett IV, Busakhala N, Opakas J, Maurer T, Martin J, Kiprono S, Freeman EE. *Impact of a multicomponent navigation strategy on stigma among people living with HIV and Kaposi's sarcoma in Kenya: a qualitative analysis*. *J Natl Cancer Inst Monogr*. **2024 Jun 5**;2024(63):38-44. doi: 10.1093/jncimonographs/lgae017. PMID: 38836529; PMCID: PMC11151333.
20. **Waite C**, Asiimwe SP, Ojara FW, Nakijoba R, Kawuma AN, **Castelnuovo B**. *Attaining Equity of Access to Research: Perspective on Research in Pregnancy and Breastfeeding Following Dolores Shockley Lecture at ASCPT2024*. *Clin Pharmacol Ther*. **2024 Jun 12**. doi: 10.1002/cpt.3344. Epub ahead of print. PMID: 38864678.
21. Ssemasaazi AJ, Kalyesubula R, Manabe YC, Mbabazi P, Naikooba S, Ssekindi F, Nasuuna E, Kibwika PB, **Castelnuovo B**. *Higher prevalence of kidney function impairment among older people living with HIV in Uganda*. *Res Sq [Preprint]*. **2024 May 13**:rs.3.rs-4364155. doi: 10.21203/rs.3.rs-4364155/v1. PMID: 38798422; PMCID: PMC1118683.

22. **Sekaggya-Wiltshire C**, Mbabazi I, Nabisere-Arinaitwe R, Banturaki G, Alinaitwe L, Otalo B, Aber F, Nampala J, Owor R, Bayiga J, Laker Agnes Odongpiny E, Castelnuovo B, Mayito J, Sekadde M, Pasipanodya JG, Turyahabwe S, Zawedde-Muyanja S. *Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy*. (PAnDoRA-3HP study): An Observational Study Protocol. medRxiv [Preprint]. **2024 Jun 2**:2024.06.01.24308310. doi: 10.1101/2024.06.01.24308310. PMID: 38853861; PMCID: PMC11160854.
23. **Nakanjako D**, Nabatanzi R, Ssinabulya I, Bayigga L, Kiragga A, Banturaki G, Castelnuovo B. *Chronic immune activation and accelerated immune aging among HIV-infected adults receiving suppressive antiretroviral therapy for at least 12 years in an African cohort*. Heliyon. **2024 May 24**;10(11):e31910. doi: 10.1016/j.heliyon.2024.e31910. PMID: 38882354; PMCID: PMC11177148.
24. Kityo C, Mambule IK, Musaaazi J, Sokhela S, Mugerwa H, Ategeka G, **Cresswell F**, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; **CARES trial team**. *Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial*. Lancet Infect Dis. **2024 May 28**:S1473-3099(24)00289-5. doi: 10.1016/S1473-3099(24)00289-5. Epub ahead of print. PMID: 38821073.
25. **Mujugira A**, Muwonge T, Aliganyira B, **Okoboi S**. *Uganda's Anti-Homosexuality Act undermines public health*. J Int AIDS Soc. **2024 May**;27(5):e26259. doi: 10.1002/jia2.26259. PMID: 38712671; PMCID: PMC11075067.
26. Kimuda S, Kwizera R, Dai B, Kigozi E, Kasozi D, Rutakingirwa MK, Tukundane A, Shifah N, Luggya T, Luswata A, Ndyetukira JF, Yueh S, Mulwana S, Wele A, Bahr NC, **Meya DB**, Boulware DR, Skipper CP. *Comparison of early fungicidal activity and mortality between daily liposomal amphotericin B and daily amphotericin B deoxycholate among patients with HIV-associated cryptococcal meningitis*. Clin Infect Dis. **2024 Jun 29**:ciae326. doi: 10.1093/cid/ciae326. Epub ahead of print. PMID: 38943665.(No PDF)
27. Wang F, Rademeyer K, Namuju OC, Abdusalaamu K, Fisher J, **Meya DB**, McRae M, Boulware DR, Lukande R, Nicol MR. *Post-mortem analysis of dolutegravir, tenofovir, lamivudine and efavirenz penetration in multiple CNS compartments*. J Infect Dis. **2024 Jun 20**:jjae325. doi: 10.1093/infdis/jjae325. Epub ahead of print. PMID: 38900910.
28. **Okurut S**, Boulware DR, Manabe YC, Tugume L, Skipper CP, Ssebambulidde K, Rhein J, Musubire AK, Akampurira A, Okafor E, Olobo JO, Janoff EN, Meya DB; ASTRO Trial Team.. *Impact of Cerebrospinal Fluid Leukocyte Infiltration and Neuroimmune Mediators on Survival with HIV-Associated Cryptococcal Meningitis*. medRxiv [Preprint]. **2024 May 31**:2024.05.29.24308130. doi: 10.1101/2024.05.29.24308130. PMID: 38854002; PMCID: PMC11160828.
29. Hale G, Adzemovic T, Huppler Hullsiek K, Mulwana S, Ndyetukira JF, Sadiq A, Kabahubya M, Ayebare P, Nankungu L, Namudde A, Namanda S, Menya G, Nakitto G, Muzoora C, Nuwagira E, Rhein J, **Meya DB**, Boulware DR, Ellis J, Abassi M. *Mid-Upper Arm Circumference Is a Strong Predictor of Mortality Among Ugandan Adults With HIV-Associated Cryptococcal Meningitis: A Prospective Cohort Study*. Open Forum Infect Dis. **2024 Jun 29**;11(7):ofae354. doi: 10.1093/ofid/ofae354. PMID: 39055123; PMCID: PMC11272084.
30. Chang A, Loy CJ, Eweis-LaBolle D, Lenz JS, Steadman A, Andgrama A, Nhung NV, Yu C, **Worodria W**, Denkinger CM, Nahid P, Cattamanchi A, De Vlaminck I. *Circulating cell-free RNA in blood as a host response biomarker for detection of tuberculosis*. Nat Commun. **2024 Jun 10**;15(1):4949. doi: 10.1038/s41467-024-49245-6. PMID: 38858368; PMCID: PMC11164910.
31. Derendinger B, Mochizuki TK, Marcelo D, Shankar D, Mangeni W, Nguyen H, Yarikaya S, **Worodria W**, Yu C, Nguyen NV, Christopher DJ, Theron G, Phillips PPJ, Nahid P, Denkinger CM, Cattamanchi A, Yoon C. *C-reactive protein-based tuberculosis triage testing: a multi-country diagnostic accuracy study*. medRxiv [Preprint]. **2024 Apr 24**:2024.04.23.24305228. doi: 10.1101/2024.04.23.24305228. PMID: 38712173; PMCID: PMC11071588.

32. **Worodria W**, Castro R, Kik SV, Dalay V, Derendinger B, Festo C, Nguyen TQ, Raberahona M, Sudarsan S, Andama A, Thangakunam B, Lyimo I, Nguyen VN, Rakotoarivelo R, Theron G, Yu C, Denkinger CM, Lapierre SG, Cattamanchi A, Christopher DJ, Jaganath D; R2D2 TB Network. *An independent, multi-country head-to-head accuracy comparison of automated chest x-ray algorithms for the triage of pulmonary tuberculosis*. medRxiv [Preprint]. **2024 Jun 19**:2024.06.19.24309061. doi: 10.1101/2024.06.19.24309061. PMID: 38946949; PMCID: PMC11213091.
33. Crowder R, Thangakunam B, Andama A, Christopher DJ, Dalay V, Dube-Nwamba W, Kik SV, Nguyen DV, Nhung NV, Phillips PP, Ruhwald M, Theron G, **Worodria W**, Yu C, Nahid P, Cattamanchi A, Gupta-Wright A, Denkinger CM; R2D2 TB Network. *Head-to-head comparison of diagnostic accuracy of TB screening tests: Chest-X-ray, Xpert TB host response, and C-reactive protein*. medRxiv [Preprint]. **2024 Jun 21**:2024.06.20.24308402. doi: 10.1101/2024.06.20.24308402. PMID: 38947093; PMCID: PMC11213098.
34. Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L, Bukirwa A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nassuna I, Nyawere J, Nakaweesa A, Cook C, Phillips P, Nalugwa T, Bachman CM, Semitala FC, Weigl BH, Connolly J, **Worodria W**, Cattamanchi A. *New Manual Quantitative Polymerase Chain Reaction Assay Validated on Tongue Swabs Collected and Processed in Uganda Shows Sensitivity That Rivals Sputum-based Molecular Tuberculosis Diagnostics*. Clin Infect Dis. **2024 May 15**;78(5):1313-1320. doi: 10.1093/cid/ciae041. PMID: 38306491; PMCID: PMC11093664.
35. Wekiya E, Mujuzi GP, Nakiyingi J, Sanya J, Matovu M, Guido O, Nakaweesi J, Karamagi C, Nakayaga JK, Mutebi EI, **Nakanjako D**. *The clinical utility of cystatin C based eGFR in assessing renal function among HIV/AIDS patients on ART at Mildmay Uganda*. BMC Nephrol. **2024 Apr 23**;25(1):144. doi: 10.1186/s12882-024-03581-3. PMID: 38654183; PMCID: PMC11036554.
36. Serraino R, Cesana BM, Morrone HL, Marino GG, Cirillo M, Olivadese V, Kyambadde P, Biriwo LS, Mutebi F, Treçarichi EM, Musinguzi P, **Byakika-Kibwika P**, Torti C. *Utility, acceptability and applicability of a nucleic acid amplification test in comparison with a syndromic approach in the management of sexually transmitted diseases at Mulago National Referral Hospital in Uganda (ASTRHA): protocol for an open-label, randomised controlled trial*. BMJ Open. **2024 Jun 11**;14(6):e084806. doi: 10.1136/bmjopen-2024-084806. PMID: 38862220; PMCID: PMC11168150.
37. van der Wekken-Pas L, Nassiwa S, Malaba T, **Lamorde M**, Myer L, Waitt C, Reynolds H, Khoo S, He N, van Leeuwen L, Burger D, Wang D, Colbers A. *Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV*. AIDS. **2024 Jun 1**;38(7):975-981. doi: 10.1097/QAD.0000000000003852. Epub 2024 Mar 6. PMID: 38277390; PMCID: PMC11064908.
38. Nuwamanya E, Nassiwa SC, Kuznik A, Waitt C, Malaba T, Myer L, Colbers A, Read J, Wang D, **Lamorde M**. *Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda*. Value Health Reg Issues. **2024 Jun 20**;44:101017. doi: 10.1016/j.vhri.2024.101017. Epub ahead of print. PMID: 38905817.
39. Székely R, Sossen B, Mukoka M, Muyoyeta M, Nakabugo E, Hella J, Nguyen HV, Ubolyam S, Chikamatsu K, Macé A, Vermeulen M, Centner CM, Nyangu S, Sanjase N, Sasamalo M, Dinh HT, Ngo TA, Manosuthi W, Jirajariyavej S, Mitarai S, Nguyen NV, Avihingsanon A, Reither K, **Nakiyingi L**, Kerkhoff AD, MacPherson P, Meintjes G, Denkinger CM, Ruhwald M; FujiLAM Study Consortium. *Prospective multicentre accuracy evaluation of the FUJIFILM SILVAMP TB LAM test for the diagnosis of tuberculosis in people living with HIV demonstrates lot-to-lot variability*. PLoS One. **2024 May 31**;19(5):e0303846. doi: 10.1371/journal.pone.0303846. PMID: 38820372; PMCID: PMC11142480.
40. Jessani A, Berry-Moreau T, Parmar R, Athanasakos A, Prodger JL, **Mujugira A**. *Healthcare access and barriers to utilization among transgender and gender diverse people in Africa: a systematic review*. BMC Glob Public Health. **2024**;2(1):44. doi: 10.1186/s44263-024-00073-2. Epub **2024 Jun 27**. PMID: 38948028; PMCID: PMC11208260.

41. Thomas D, Nalumansi A, Reichman M, Metitiri M, Nambi F, Kibuuka J, Nakabugo L, Kamusiime B, Kasiita V, Nalukwago GK, Muwonge TR, Simoni J, Montgomery ET, **Mujugira A**, Heffron R. *Implementation of gender-based violence screening guidelines in public HIV treatment programs: A mixed methods evaluation in Uganda*. PLOS Glob Public Health. **2024 Jun 4**;4(6):e0003185. doi: 10.1371/journal.pgph.0003185. PMID: 38833452; PMCID: PMC11149855.
42. Ellis J, Nsangi L, Bangdiwala A, Hale G, Gakuru J, Kagimu E, Mugabi T, Kigozi E, Tukundane A, Okirwoth M, Kandole TK, Cresswel F, Harrison TS, Moore D, Fielding K, **Meja D**, Boulware D, Jarvis JN. *Integrated management of cryptococcal meningitis and concurrent opportunistic infections to improve outcomes in advanced HIV disease: a randomised strategy trial*. Wellcome Open Res. **2024 Jun 5**;9:14. doi: 10.12688/wellcomeopenres.19324.2. PMID: 38854693; PMCID: PMC11157187.
43. Okwir M, Link A, Opio B, Okello F, Nakato R, Nabongo B, Alal J, Rhein J, **Meja D**, Liu Y, Bohjanen PR. *Poor long-term outcomes despite improved hospital survival for patients with cryptococcal meningitis in rural, Northern Uganda*. PLoS One. **2024 May 21**;19(5):e0303805. doi: 10.1371/journal.pone.0303805. PMID: 38771769; PMCID: PMC11108149.
44. **Nabukenya S**, Kyaddondo D, Munabi IG, Waitt C, Twimukye A, Mwaka ES. *The role of community engagement in promoting research participants' understanding of pharmacogenomic research results: Perspectives of stakeholders involved in HIV/AIDS research and treatment*. PLoS One. **2024 Apr 2**;19(4):e0299081. doi: 10.1371/journal.pone.0299081. PMID: 38564575; PMCID: PMC10986979.

Jan – March 2024:

45. Wagner GJ, Bogart LM, Matovu JKB, **Okoboi S**, Gwokyalya V, Ninsiima S, McBain RK, Storholm ED, Malika N, Green HD. *Correlates of HIV Prevention Advocacy by Persons Living with HIV in Kampala, Uganda: A Cross-sectional Evaluation of a Conceptual Model*. Int J Behav Med. **2024 Mar 22**. doi: 10.1007/s12529-024-10277-3. Epub ahead of print. PMID: 38519810.
46. Kpokiri EE, McDonald K, Abraha YG, Osorio L, Nath TC, Talavera-Urdanivia VA, Akinwale OP, Manabe YC, **Castelnuovo B**, Tang W, Yilma D, Mihut M, Ezechi O, Iwelunmor J, Kaba M, Abdissa A, Tucker JD. *Health research mentorship in low-income and middle-income countries: a global qualitative evidence synthesis of data from a crowdsourcing open call and scoping review*. BMJ Glob Health. **2024 Jan 6**;9(1):e011166. doi: 10.1136/bmjgh-2022-011166. PMID: 38184299; PMCID: PMC10773352.
47. Walker LE, Nakyeeyune L, Ashaba A, Ahebwa S, Nakijoba R, Asiimwe SP, Kiragga A, **Castelnuovo B**, **Waitt C**. *Public Attitudes Towards Access to Health Data for Research Purposes Through Citizens' Jury in Uganda*. Stud Health Technol Inform. **2024 Jan 25**;310:129-133. doi: 10.3233/SHTI230941. PMID: 38269779.
48. **Senkoro E**, Mbabazi P, Banturaki G, Naikoba S, **Castelnuovo B**. *The impact of geriatric syndromes on quality of life among older people living with HIV in Kampala, Uganda*. Front Public Health. **2024 Jan 23**;12:1306151. doi: 10.3389/fpubh.2024.1306151. PMID: 38322125; PMCID: PMC10845335.
49. **Izudi J**, Cattamanchi A, **Castelnuovo B**, King R. *Barriers and facilitators to viral load suppression among people living with HIV following intensive adherence counseling in Kampala, Uganda: A qualitative study*. Soc Sci Med. 2024 Feb;343:116595. doi: 10.1016/j.socscimed.2024.116595. Epub 2024 Jan 14. PMID: 38242033. **(PDF-Restricted access)**
50. **Kigongo VJ**, Nankabirwa JI, Kitutu FE, Ssenyonga R, Mutebi RK, Kazibwe A, Kiguba R, **Kambugu AD**, **Castelnuovo B**. *Dyslipidemia among adult people living with HIV on dolutegravir - based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants*. BMC Infect Dis. **2024 Jan 5**;24(1):53. doi: 10.1186/s12879-023-08892-8. PMID: 38183002; PMCID: PMC10770888.
51. Hamill MM, **Onzia A**, Parkes-Ratanshi RM, Kyambadde P, Mande E, Nakate V, Melendez JH, Gough E, Manabe YC. *Antibiotic overuse, poor antimicrobial stewardship, and low specificity of syndromic case management in a cross section of men with urethral discharge syndrome in Kampala, Uganda*. PLoS One. **2024 Mar 15**;19(3):e0290574. doi: 10.1371/journal.pone.0290574. PMID: 38489281; PMCID: PMC10942085.

52. Chang CC, Harrison TS, Bicanic TA, Chayukulkeeree M, Sorrell TC, Warris A, Hagen F, Spec A, Oladele R, Govender NP, Chen SC, Mody CH, Groll AH, Chen YC, Lionakis MS, Alanio A, Castañeda E, Lizarazo J, Vidal JE, Takazono T, Hoenigl M, Alffenaar JW, Gangneux JP, Soman R, Zhu LP, Bonifaz A, Jarvis JN, Day JN, Klimko N, Salmanton-García J, Jouvion G, **Meya DB**, Lawrence D, Rahn S, Bongomin F, McMullan BJ, Sprute R, Nyazika TK, Beardsley J, Carlesse F, Heath CH, Ayanlowo OO, Mashedi OM, Queiroz-Telles Filho F, Hosseinipour MC, Patel AK, Temfack E, Singh N, Cornely OA, Boulware DR, Lortholary O, Pappas PG, Perfect JR. *Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM*. *Lancet Infect Dis*. **2024 Feb 9**;S1473-3099(23)00731-4. doi: 10.1016/S1473-3099(23)00731-4. Epub ahead of print. PMID: 38346436. **(Restricted PDF Access)**
53. Ellis J, **Meya DB**, Cresswell FC. *Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults*. *N Engl J Med*. **2024 Jan 25**;390(4):382-383. doi: 10.1056/NEJMc2313671. PMID: 38265655. **(PDF No Access)**
54. Bongomin F, Kwizera R, Namusobya M, van Rhijn N, Andia-Biraro I, Kirenga BJ, **Meya DB**, Denning DW. *Re-estimation of the burden of serious fungal diseases in Uganda*. *Ther Adv Infect Dis*. **2024 Feb 6**;11:20499361241228345. doi: 10.1177/20499361241228345. PMID: 38328511; PMCID: PMC10848809.
55. Osaigbovo II, Govender NP, Jordan AM, Bongomin F, **Meya DB**, Kanyua A, Mashedi OM, Koffi D, Loyse A, Sturny-Leclère A, Gangneux JP, Denning DW, Chiller T, Cornely OA, Oladele RO. *The Nairobi Declaration 2023: A commitment to address deadly yet neglected fungal diseases in Africa*. *Med Mycol*. **2024 Jan 9**;62(1):myad141. doi: 10.1093/mmy/myad141. PMID: 38154488.
56. Wang L, Muwonge TR, Simoni JM, Nambi F, Nakabugo L, Kibuuka J, Thomas D, Katz IT, Feutz E, Thomas KK, Ware NC, Wyatt MA, Kadama H, **Mujugira A**, Heffron R; Partners PrEP Program Study Team. *Behavioral Modeling and its Association with PrEP and ART Use in Ugandan HIV-Serodifferent Couples*. *AIDS Behav*. **2024 Feb 16**. doi: 10.1007/s10461-024-04286-2. Epub ahead of print. PMID: 38361169. **(No PDF)**
57. Wyatt MA, Pisarski EE, Nalumansi A, Kasiita V, Kamusiime B, Nalukwago GK, Thomas D, Muwonge TR, **Mujugira A**, Heffron R, Ware NC; Partners PrEP Program Study Team. *How PrEP delivery was integrated into public ART clinics in central Uganda: A qualitative analysis of implementation processes*. *PLOS Glob Public Health*. **2024 Mar 7**;4(3):e0002916. doi: 10.1371/journal.pgph.0002916. PMID: 38452111; PMCID: PMC10919847..
58. Zewdie K, Kiweewa FM, Ssebuliba T, Morrison SA, Muwonge TR, Boyer J, Bambia F, Badaru J, Stein G, Mugwanya KK, Wyatt C, Yin MT, **Mujugira A**, Heffron R. *The effect of daily oral PrEP use during pregnancy on bone mineral density among adolescent girls and young women in Uganda*. *Front Reprod Health*. **2024 Jan 8**;5:1240990. doi: 10.3389/frph.2023.1240990. PMID: 38260049; PMCID: PMC10801233.
59. Kamusiime B, Beima-Sofie K, Chhun N, Nalumansi A, Nalukwago GK, Kasiita V, Twesige CC, Kansime R, Muwonge TR, Kyambadde P, Kadama H, Mudiope P, Glick S, Lambdin B, **Mujugira A**, Heffron R. *"Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda*. *Addict Sci Clin Pract*. **2024 Feb 23**;19(1):13. doi: 10.1186/s13722-024-00444-y. PMID: 38395940; PMCID: PMC10893723.
60. Mpirirwe R, **Mujugira A**, Walusaga H, Ayebare F, Musanje K, Ndugga P, Muhumuza C, Nangendo J, Semitala FC, Kyambadde P, Kalyango J, Kiragga A, Karamagi C, Kanya MR, Armstrong-Hough M, Katahoire AR. *Perspectives of female sex workers on HIV pre-exposure prophylaxis delivery in Uganda: A qualitative study*. *Res Sq [Preprint]*. **2024 Mar 21**:rs.3.rs-4115528. doi: 10.21203/rs.3.rs-4115528/v1. PMID: 38562811; PMCID: PMC10984088.
61. Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, Baeten JM, Liu A, Hoover KW, Celum C, Grinsztejn B, Morris S, Wheeler DP, Mayer KH, Golub SA, Bekker LG, Diabaté S, Hoornenborg E, Myers J, Leech AA, McCormack S, Chan PA, Sweat M, Matthews LT, Grant R; Global F/TDF **PrEP Study Team**. *HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies*. *Clin Infect Dis*. **2024 Mar 14**:ciae143. doi: 10.1093/cid/ciae143. Epub ahead of print. PMID: 38484128.

62. Klabbers RE, Parrish C, Iraguha P, Ntuyenabo MK, Ajidiru S, Nshimiyimana V, Caroline K, Faustin Z, Sveum EM, **Muwonge TR**, O’Laughlin KN. *Characterizing Mobility and its Association with HIV Outcomes in Refugee Settlements in Uganda*. *Ann Glob Health*. **2024 Mar 25**;90(1):23. doi: 10.5334/aogh.4367. PMID: 38550610; PMCID: PMC10976981.
63. Tusabe F, **Lamorde M**, Medley A, **Kesande M**, Lozier MJ, **Yapswale S**, **Ociti F**, **Isabirye H**, **Nuwamanya E**, **Nanyondo J**, Boore A, Vosburgh W, Kasule JN, Pratt C, Berendes D. *Establishment of District-Led Production of WHO-Recommended Alcohol-based Hand Rub (ABHR) during the COVID-19 Pandemic: A Model for Improving Access to ABHR during Health Emergencies*. *J Water Sanit Hyg Dev*. 2023;13(10):847-856. doi: 10.2166/washdev.2023.143. PMID: 38410156; PMCID: PMC10896262.
64. **Twimukye A**, Alhassan Y, Ringwald B, Malaba T, Myer L, **Waite C**, **Lamorde M**, Reynolds H, Khoo S, Taegtmeier M. *Support, not blame: safe partner disclosure among women diagnosed with HIV late in pregnancy in South Africa and Uganda*. *AIDS Res Ther*. **2024 Mar 13**;21(1):14. doi: 10.1186/s12981-024-00600-z. PMID: 38481233; PMCID: PMC10938717.
65. van der Wekken-Pas L, Nassiwa S, Malaba T, **Lamorde M**, Myer L, **Waite C**, Reynolds H, Khoo S, He N, van Leeuwen L, Burger D, Wang D, Colbers A. *Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DoIPHIN2 substudy*. *AIDS*. **2024 Mar 7**. doi: 10.1097/QAD.0000000000003852. Epub ahead of print. PMID: 38277390. **(No PDF)**
66. Abd El Wahed A, Kadetz P, Okuni JB, Dieye Y, Frimpong M, Ademowo GO, Makiala-Mandanda S, Woldeamanuel Y, Eltom KH, Yeboah G, Käsbohrer A, Kajumbula H, Truyen U, **Nakanjako D**. *An African One Health network for antimicrobial resistance and neglected tropical diseases*. *Nat Med*. **2024 Jan**;30(1):10-11. doi: 10.1038/s41591-023-02666-0. PMID: 38172632. **(No PDF)**
67. Nanyeenya N, **Nakanjako D**, Makumbi F, Nakigozi G, Nalugoda F, Kigozi G, Nasuuna E, Kibira SPS, Nabadda S, Kiyaga C, Huzafah M, Kiwanuka N. *Effectiveness of intensive adherence counselling in achieving an undetectable viral load among people on antiretroviral therapy with low-level viraemia in Uganda*. *HIV Med*. **2024 Feb**;25(2):245-253. doi: 10.1111/hiv.13568. Epub 2023 Oct 18. PMID: 37853605. **(No PDF)**
68. Liu Yin J, Satapathy SK, O’Beirne J, **Ocama P**, Dar O, Duseja A, Schiano T, Ala A. *Transforming global hepatology training: a call for action*. *Lancet Gastroenterol Hepatol*. **2024 Mar**;9(3):197-199. doi: 10.1016/S2468-1253(23)00400-4. Epub 2024 Jan 15. PMID: 38237622.
69. Fouad Y, Ghazinyan H, Alborai M, Al Khatry M, Desalegn H, Al-Ali F, El-Shabrawi MHF, **Ocama P**, Derbala M, Barakat S, Awuku YA, Ndububa DA, Sabbah M, Hamoudi W, Ng’wanasayi M, Elwakil R, Ally R, Al-Busafi SA, Hashim A, Esmat G, Shiha G. *Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition*. *J Hepatol*. **2024 Feb 10**:S0168-8278(24)00112-0. doi: 10.1016/j.jhep.2024.01.033. Epub ahead of print. PMID: 38342440.
70. Picchio CA, Nicolàs A, Ayemfouo Fofou IV, Kasone V, Guewo-Fokeng M, Tagny CT, Nanyonjo T, Nansumba H, Kouongni YN, Sezawo Kamdjeu RGE, Seremba E, Kouanfack C, Ssewanyana I, Njouom R, Segura AR, Rodríguez-Frías F, Mbanya JC, **Ocama P**, Lazarus JV. *Acceptability and Feasibility of the Plasma Separation Card for an Integrated Model of Care for HBV and HCV Screening Among People Attending HIV Clinics in Cameroon and Uganda*. *J Epidemiol Glob Health*. **2024 Mar 27**. doi: 10.1007/s44197-024-00220-w. Epub ahead of print. PMID: 38536619.
71. Komakech K, **Nakiyingi L**, Fred A, Achan B, Joloba M, Kirenga BJ, Ssengooba W. *Effect of mixed Mycobacterium tuberculosis infection on rapid molecular diagnostics among patients starting MDR-TB treatment in Uganda*. *BMC Infect Dis*. **2024 Jan 10**;24(1):70. doi: 10.1186/s12879-023-08968-5. PMID: 38200467; PMCID: PMC10782568.
72. Gupta-Wright A, Ha H, Abdulgadar S, Crowder R, Emmanuel J, Mukwatamundu J, Marcelo D, Phillips PPJ, Christopher DJ, Nhung NV, Theron G, Yu C, Nahid P, Cattamanchi A, **Worodria W**, Denkinger CM; R2D2 TB Network. *Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa*. *Lancet Glob Health*. **2024 Feb**;12(2):e226-e234. doi: 10.1016/S2214-109X(23)00541-7. PMID: 38245113.

73. Baluku JB, Namiro S, Namanda B, Nabwana M, Andia-Biraro I, **Worodria W**, Salata R, Mfinanga S, Gerson S, Kirenga B. *Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Distinguishing Lung Cancer in People with HIV*. *Dis Markers*. **2024 Jan 23**;2024:8822024. doi: 10.1155/2024/8822024. PMID: 38292339; PMCID: PMC10827363.
74. Huddart S, Yadav V, Sieberts SK, Omberg L, Raberahona M, Rakotoarivelo R, Lyimo IN, Lweno O, Christopher DJ, Nhung NV, Theron G, **Worodria W**, Yu CY, Bachman CM, Burkot S, Dewan P, Kulhare S, Small PM, Cattamanchi A, Jaganath D, Lapierre SG. *Solicited Cough Sound Analysis for Tuberculosis Triage Testing: The CODA TB DREAM Challenge Dataset*. medRxiv [Preprint]. **2024 Mar 28**:2024.03.27.24304980. doi: 10.1101/2024.03.27.24304980. PMID: 38585855; PMCID: PMC10996751.
75. Abelman RA, Fitzpatrick J, Byanova KL, Zawedde J, Sanyu I, Byanyima P, Musisi E, Hsieh J, Zhang M, Branchini J, Sessolo A, Hunt PW, Lalitha R, Davis JL, Crothers K, **Worodria W**, Huang L. *Sex and HIV Differences in Preserved Ratio Impaired Spirometry (PRISm) Among Ugandans Postpneumonia*. *Open Forum Infect Dis*. **2024 Jan 22**;11(3):ofae033. doi: 10.1093/ofid/ofae033. PMID: 38456193; PMCID: PMC10919919.
76. Kirenga BJ, Chakaya J, Yimer G, Nyale G, Haile T, Muttamba W, Mugenyi L, Katagira W, **Worodria W**, Aanyu-Tukamuhebwa H, Lugogo N, Joloba M, Mersha TB, Bekele A, Makumbi F, Mekasha A, Green CL, de Jong C, Kanya M, van der Molen T. *The burden of severe asthma in sub-Saharan Africa: Findings from the African Severe Asthma Project*. *J Allergy Clin Immunol Glob*. **2024 Jan 9**;3(2):100209. doi: 10.1016/j.jacig.2024.100209. PMID: 38328803; PMCID: PMC10847773.
77. Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L, Bukirwa A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nassuna I, Nyawere J, Nakaweesa A, Cook C, Phillips P, Nalugwa T, Bachman CM, Semitala FC, Weigl BH, Connelly J, **Worodria W**, Cattamanchi A. *New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics*. *Clin Infect Dis*. **2024 Feb 2**:ciae041. doi: 10.1093/cid/ciae041. Epub ahead of print. PMID: 38306491.
78. Kibirige D, Andia-Biraro I, Olum R, Adakun S, **Zawedde-Muyanja S**, Sekaggya-Wiltshire C, Kimuli I. *Tuberculosis and diabetes mellitus comorbidity in an adult Ugandan population*. *BMC Infect Dis*. **2024 Feb 22**;24(1):242. doi: 10.1186/s12879-024-09111-8. PMID: 38389045; PMCID: PMC10885501.
79. Wennemann S, Mudarshiru B, **Zawedde-Muyanja S**, Siddharthan T, Jackson PD. *The effect of biomass smoke exposure on quality-of-life among Ugandan patients treated for tuberculosis: A cross-sectional analysis*. *PLOS Glob Public Health*. **2024 Feb 8**;4(2):e0002892. doi: 10.1371/journal.pgph.0002892. PMID: 38330053; PMCID: PMC10852290.
80. Bbuye M, **Muyanja SZ**, Sekitoleko I, Padalkar R, Robertson N, Helwig M, Hopkinson D, Siddharthan T, Jackson P. *Patient level barriers to accessing TB care services during the COVID-19 pandemic in Uganda, a mixed methods study*. *BMC Health Serv Res*. **2024 Jan 10**;24(1):52. doi: 10.1186/s12913-023-10513-8. PMID: 38200524; PMCID: PMC10782633.
- 81. Izudi J**, Bajunirwe F. *Case fatality rate for Ebola disease, 1976-2022: A meta-analysis of global data*. *J Infect Public Health*. **2024 Jan**;17(1):25-34. doi: 10.1016/j.jiph.2023.10.020. Epub 2023 Oct 27. PMID: 37992431.
82. Nabukalu D, Yiannoutsos CT, **Semeere A**, Musick BS, Murungi T, Namulindwa JV, Waswa F, Nakigozi G, Sewankambo NK, Reynolds SJ, Lutalo T, Makumbi F, Kigozi G, Nalugoda F, Wools-Kaloustian K. *Mortality Among HIV-Infected Adults on Antiretroviral Therapy in Southern Uganda*. *J Acquir Immune Defic Syndr*. **2024 Mar 1**;95(3):268-274. doi: 10.1097/QAI.0000000000003330. PMID: 38408217; PMCID: PMC10898547.
83. Morales AE, Gumenick R, Genovese CM, Jang YY, Ouedraogo A, Ibáñez de Garayo M, Pannellini T, Patel S, Bott ME, Alvarez J, Mun SS, Totonchy J, Gautam A, Delgado de la Mora J, Chang S, Wirth D, Horenstein M, Dao T, Scheinberg DA, Rubinstein PG, **Semeere A**, Martin J, Godfrey CC, Moser CB, Matining RM, Campbell TB, Borok MZ, Krown SE, Cesarman E. *Wilms' tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP*. *PLoS Pathog*. **2024 Jan 8**;20(1):e1011881. doi: 10.1371/journal.ppat.1011881. PMID: 38190392; PMCID: PMC10898863.

84. Mungo C, Orang’o O, Ofner S, Musick B, Yiannoutsos C, Cohen CR, Brown D, Wools-Kaloustian K, **Semeere A**. *Real-World Cervical Cancer Screening Uptake and Predictors of Visual Inspection With Acetic Acid Positivity Among Women Living With HIV in Care Programs in Western Kenya*. *JCO Glob Oncol*. **2024 Feb**;10:e2300311. doi: 10.1200/GO.23.00311. PMID: 38359369; PMCID: PMC10881085.
85. Laban M, Nakku EJ, Nangendo J, Muramuzi D, Akello F, Bakeera SK, Semitala FC, **Semeere AS**, Karamagi C. *Acceptability of short message service reminders as the support tool for PrEP adherence among young women in Mukono district, Uganda*. *PLOS Glob Public Health*. **2024 Jan 2**;4(1):e0002492. doi: 10.1371/journal.pgph.0002492. PMID: 38165833; PMCID: PMC10760663.
86. Owachi D, Akatukunda P, Nyananzi DS, Katwesigye R, Wanyina S, Muddu M, Kawuma S, **Kalema N**, Kabugo C, Semitala FC. *Mortality and associated factors among people living with HIV admitted at a tertiary-care hospital in Uganda: a cross-sectional study*. *BMC Infect Dis*. **2024 Feb 22**;24(1):239. doi: 10.1186/s12879-024-09112-7. PMID: 38388345; PMCID: PMC10885437.
87. Kibirige D, **Owarwo N**, Kyazze AP, Morgan B, Olum R, Bongomin F, Andia-Biraro I. *Prevalence, Clinical Features, and Predictors of Adrenal Insufficiency in Adults With Tuberculosis or HIV: A Systematic Review and Meta-analysis*. *Open Forum Infect Dis*. **2024 Feb 22**;11(4):ofae098. doi: 10.1093/ofid/ofae098. PMID: 38560601; PMCID: PMC10981394.
88. Dixon EG, Rasool S, **Otaalo B**, Motee A, Dear JW, Sloan D, Stagg HR. *No action is without its side effects: Adverse drug reactions and missed doses of antituberculosis therapy, a scoping review*. *Br J Clin Pharmacol*. **2024 Jan**;90(1):313-320. doi: 10.1111/bcp.15908. Epub 2023 Oct 9. PMID: 37712491; PMCID: PMC10952801.

Oct – Dec 2023:

89. **Nabatanzi R**, Ssekamatte P, Castelnovo B, Kambugu A, Nakanjako D. *Increased Levels of Caspase-1 and IL-1 β Among Adults With Persistent Immune Activation After 12 Years of Suppressive Antiretroviral Therapy in the Infectious Diseases Institute HIV Treatment Cohort*. *Open Forum Infect Dis*. **2023 Nov 7**;10(11):ofad539. doi: 10.1093/ofid/ofad539. PMID: 37953818; PMCID: PMC10638490.(No PDF)
90. Karmali DN, Argento AC, Kirenga B, Batra H, Lee HJ, MacRosty CR, Lerner GR, Siddharthan T, **Worodria W**, Jackson P. *A Longitudinal Study of Multimodal Bronchoscopy Training in Uganda*. *ATS Sch*. **2023 Feb 8**;4(2):152-163. doi: 10.34197/ats-scholar.2022-00800C. PMID: 37538081; PMCID: PMC10394594.
91. **Mulindwa F**, Castelnovo B, Brusselaers N, Bollinger R, Yendewa G, Amutuhairu W, Mukashaka C, Schwarz JM. *Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report*. *BMC Infect Dis*. **2023 Oct 30**;23(1):744. doi: 10.1186/s12879-023-08712-z. PMID: 37904127; PMCID: PMC10617153.
92. Senteza I, **Castelnovo B**, Mukunya D, Makumbi F. *Virological non-suppression among adult males attending HIV care services in the fishing communities in Bulisa district, Uganda*. *PLoS One*. **2023 Oct 19**;18(10):e0293057. doi: 10.1371/journal.pone.0293057. PMID: 37856568; PMCID: PMC10586650.
93. **Tugume L**, Ssebambulidde K, Kasibante J, Ellis J, Wake RM, Gakuru J, Lawrence DS, Abassi M, Rajasingham R, **Meya DB**, Boulware DR. **Cryptococcal meningitis**. *Nat Rev Dis Primers*. **2023 Nov 9**;9(1):62. doi: 10.1038/s41572-023-00472-z. PMID: 37945681.(No PDF)
94. **Meya DB**, Meintjes G. *HIV-related CNS infections: translating DREAMM into reality*. *Lancet HIV*. **2023 Oct**;10(10):e627-e628. doi: 10.1016/S2352-3018(23)00232-1. PMID: 37802564.(No PDF)
95. Jarvis JN, Chou R, Harrison TS, Lawrence DS, Muthoga C, Mupeli K, **Meya DB**, Mwandumba HC, Kanyama C, Meintjes G, Leeme TB, Ndhlovu CE, Beattie P, Sued O, Pérez Casas C, Makanga M, Ford N. *Translating evidence into global impact: lessons for HIV research and policy development from the AMBITION trial*. *Lancet Glob Health*. **2023 Nov**;11(11):e1688-e1690. doi: 10.1016/S2214-109X(23)00412-6. PMID: 37858577; PMCID: PMC7615252.

96. **Tugume L**, Semitala FC, Owachi D, Kagimu E, Kanya MR, Meya DB. *Clinical characteristics and morbidity among hospitalized adults with advanced HIV disease in Uganda during 'test and treat' era*. PLOS Glob Public Health. **2023 Oct 18**;3(10):e0002457. doi: 10.1371/journal.pgph.0002457. PMID: 37851597; PMCID: PMC10584089.
97. Kengo A, Nabisere R, Gausi K, Musaaazi J, Buzibye A, Omali D, Aarnoutse R, **Lamorde M**, Dooley KE, Sloan DJ, Denti P, Sekaggya-Wiltshire C. *Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin*. Antimicrob Agents Chemother. **2023 Oct 18**:e0043023. doi: 10.1128/aac.00430-23. Epub ahead of print. PMID: 37850738. **(No PDF)**
98. Makabayi-Mugabe R, Musaaazi J, **Zawedde-Muyanja S**, Kizito E, Fatta K, Namwanje-Kaweesi H, Turyahabwe S, Nkolo A. *Community-based directly observed therapy is effective and results in better treatment outcomes for patients with multi-drug resistant tuberculosis in Uganda*. BMC Health Serv Res. **2023 Nov 13**;23(1):1248. doi: 10.1186/s12913-023-10120-7. PMID: 37957610. **(No PDF)**
99. Kasprowicz VO, Jeffery C, Mbuvi D, Bukirwa V, Ouattara K, Kirimi F, Heitz-Tokpa K, Gorrethy M, Chopera D, **Nakanjako D**, Bonfoh B, Elliott A, Kinyanjui S, Bates I, Ndung'u T. *How to improve research capacity strengthening efforts: learning from the monitoring and evaluation of four research consortia in Africa*. Health Res Policy Syst. **2023 Oct 25**;21(1):109. doi: 10.1186/s12961-023-01056-9. PMID: 37880720; PMCID: PMC10601174.
100. **Ponsiano O** et al: Polaris Observatory Collaborators. *Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study*. Lancet Gastroenterol Hepatol. **2023 Oct**;8(10):879-907. doi: 10.1016/S2468-1253(23)00197-8. Epub 2023 Jul 27. PMID: 37517414. **(No PDF)**
101. **Nabukenya S**, Kyaddondo D, Twimukye A, Munabi IG, Waitt C, Mwaka ES. *'It is a complex process, but it's very important to return these results to participants'*. Stakeholders' perspectives on the ethical considerations for returning individual pharmacogenomics research results to people living with HIV. Research Ethics. **2023 Oct 31**:17470161231207739.
102. **Nabukenya S**, Waitt C, Senyonga R, **Castelnuovo B**, Munabi IG, Kyaddondo D, Mwaka ES. *Research Participants' Preferences for Individual Results of Pharmacogenomics Research: A Case of a Ugandan HIV Research Institute*. J Empir Res Hum Res Ethics. **2023 Oct**; 18(4):218-232. doi: 10.1177/15562646231187434. Epub 2023 Jul 13. PMID: 37448227. **(No PDF)**
103. Namusobya M, Bongomin F, Mukisa J, Batte C, Olwit WK, Rhein J, **Sekaggya-Wiltshire C**, Prasad S. *The Impact of Chronic Pulmonary Aspergillosis Co-infection on the Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Uganda*. Mycopathologia. **2023 Oct**;188(5):713-720. doi: 10.1007/s11046-023-00741-1. Epub 2023 May 17. PMID: 37195546.
104. Gupta-Wright A, den Boon S, MacLean EL, Cirillo D, Cobelens F, Gillespie SH, Kohli M, Ruhwald M, Savic R, Brigden G, Gidado M, Goletti D, Hanna D, Hasan R, Hewison C, Koura KG, Lienhardt C, Lungu P, McHugh TD, McKenna L, Scott C, Scriba T, **Sekaggya-Wiltshire C**, Kasaeva T, Zignol M, Denkinger CM, Falzon D. *Target product profiles: tests for tuberculosis treatment monitoring and optimization*. Bull World Health Organ. **2023 Nov 1**;101(11):730-737. doi: 10.2471/BLT.23.290901. Epub 2023 Oct 4. PMID: 37961060; PMCID: PMC10630735.
105. Ware NC, Wyatt MA, Pisarski EE, Nalumansi A, Kasiita V, Kamusiime B, Nalukwago GK, Thomas D, Kibuuka J, **Muwonge T**, **Mujugira A**, Heffron R; Partners PrEP Program Research Team. *How Central Ugandan HIV Clinics Adapted During COVID-19 Lockdown Restrictions to Promote Continuous Access to Care: A Qualitative Analysis*. AIDS Behav. **2023 Nov**;27(11):3725-3734. doi: 10.1007/s10461-023-04090-4. Epub 2023 Jun 2. PMID: 37266823; PMCID: PMC10235841.
106. Bongomin F, Ekeng BE, **Kwizera R**, Salmanton-García J, Kibone W, van Rhijn N, Govender NP, Meya DB, Osaigbovo II, Hamer DH, Oladele R, Denning DW. *Fungal diseases in Africa: Closing the gaps in diagnosis and treatment through implementation research and advocacy*. J Mycol Med. **2023 Nov**;33(4):101438. doi: 10.1016/j.mycmed.2023.101438. Epub 2023 Oct 19. PMID: 38358796. **(No PDF)**

107. McHale TC, Akampurira A, Gerlach ES, Mucunguzi A, Nicol MR, Williams DA, Nielsen K, Bicanic T, Fieberg A, Dai B, **Meya DB**, Boulware DR; ENACT Trial Team. *5-Flucytosine Longitudinal Antifungal Susceptibility Testing of Cryptococcus neoformans: A Substudy of the EnACT Trial Testing Oral Amphotericin*. Open Forum Infect Dis. **2023 Nov 29**;10(12):ofad596. doi: 10.1093/ofid/ofad596. PMID: 38143852; PMCID: PMC10745249.
108. Kengo A, Gausi K, Nabisere R, **Musaazi J**, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Sekaggya-Wiltshire C, Denti P. *Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin*. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043123. doi: 10.1128/aac.00431-23. Epub **2023 Oct 18**. PMID: 37850737; PMCID: PMC10649026.
109. Kibirige D, Andia-Biraro I, Olum R, Adakun S, Zawedde-Muyanja S, **Sekaggya-Wiltshire C**, Kimuli I. *Metabolic characterisation of adult Ugandan patients with TB and diabetes mellitus comorbidity*. Int J Tuberc Lung Dis. **2023 Dec 1**;27(12):944-945. doi: 10.5588/ijtld.23.0218. PMID: 38042976. **(No PDF)**
110. Kibirige D, Zawedde-Muyanja S, Andia-Biraro I, Olum R, Adakun S, **Sekaggya-Wiltshire C**, Kimuli I. *Diagnostic accuracy of two confirmatory tests for diabetes mellitus in adult Ugandans with recently diagnosed tuberculosis*. Ther Adv Infect Dis. **2023 Dec 21**;10:20499361231216799. doi: 10.1177/20499361231216799. PMID: 38145193; PMCID: PMC10748612.
111. Mayito J, Meya DB, Miriam A, Dhikusooka F, Rhein J, **Sekaggya-Wiltshire C**. *Monocyte to Lymphocyte ratio is highly specific in diagnosing latent tuberculosis and declines significantly following tuberculosis preventive therapy: A cross-sectional and nested prospective observational study*. PLoS One. **2023 Nov 30**;18(11):e0291834. doi: 10.1371/journal.pone.0291834. PMID: 38033005; PMCID: PMC10688757.
112. Koyuncu A, Carter RJ, **Musaazi J**, Namageyo-Funa A, Carter VM, Lamorde M, Prybylski D, Apondi R, Bakyaita T, Boore AL, Homby J, Brown VR, Kigozi J, Nabaggala MS, Nakate V, Nkurunziza E, Stowell DF, Walwema R, Olowo A, Jalloh MF. *Public perceptions of Ebola vaccines and confidence in health services to treat Ebola, malaria, and tuberculosis: Findings from a cross-sectional household survey in Uganda, 2020*. PLOS Glob Public Health. **2023 Dec 19**;3(12):e0001884. doi: 10.1371/journal.pgph.0001884. PMID: 38113241; PMCID: PMC10729951.
113. Gausi K, Mugerwa H, Siccardi M, Montanha MC, **Lamorde M**, Wiesner L, D'Avolio A, McIlleron H, Wilkins E, De Nicolò A, Maartens G, Khoo S, Kityo C, Denti P, Waitt C. *Pharmacokinetics and safety of twice-daily ritonavir-boosted atazanavir with rifampicin*. Clin Infect Dis. **2023 Nov 20**:ciad700. doi: 10.1093/cid/ciad700. Epub ahead of print. PMID: 37982585.
114. Lotspeich SC, Shepherd BE, Kariuki MA, Wools-Kaloustian K, McGowan CC, Musick B, **Semeere A**, Crabtree Ramirez BE, Mkwashapi DM, Cesar C, Ssemakadde M, Machado DM, Ngeresa A, Ferreira FF, Lwali J, Marcelin A, Cardoso SW, Luque MT, Otero L, Cortés CP, Duda SN. *Lessons learned from over a decade of data audits in international observational HIV cohorts in Latin America and East Africa*. J Clin Transl Sci. **2023 Nov 3**;7(1):e245. doi: 10.1017/cts.2023.659. PMID: 38033704; PMCID: PMC10685260.

July – Sept 2023

115. **Mulindwa F**, **Castelnuovo B**, Brusselaers N, Nabwana M, Bollinger R, Buzibye A, Agnes Odongpiny EL, Kiguba R, Schwarz JM. *Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults*. AIDS Res Ther. **2023 Sep 9**;20(1):65. doi: 10.1186/s12981-023-00564-6. PMID: 37689695; PMCID: PMC10492310.
116. **Mulindwa F**, Schwarz JM, Brusselaers N, Nabwana M, Bollinger R, Buzibye A, Amutuhaire W, Yendewa G, Laker E, Kiguba R, Castelnuovo B. *Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks*. Res Sq [Preprint]. **2023 Aug 3**:rs.3.rs-3154716. doi: 10.21203/rs.3.rs-3154716/v1. PMID: 37577475; PMCID: PMC10418540.

117. Ellis J, Bangdiwala AS, Skipper CP, Tugume L, Nsangi L, Matovu J, Pastick KA, Ssebambulidde K, Morawski BM, Musubire AK, Schleiss MR, Moore DAJ, Jarvis JN, Boulware DR, **Meya DB, Castelnovo B**. *Baseline Cytomegalovirus Viremia at Cryptococcal Meningitis Diagnosis Is Associated With Long-term Increased Incident TB Disease and Mortality in a Prospective Cohort of Ugandan Adults With HIV*. *Open Forum Infect Dis*. **2023 Sep 19**;10(9):ofad449. doi: 10.1093/ofid/ofad449. PMID: 37732168; PMCID: PMC10508356.
118. **Izudi J, Castelnovo B**, King R, Cattamanchi A. *Impact of intensive adherence counseling on viral load suppression and mortality among people living with HIV in Kampala, Uganda: A regression discontinuity design*. *PLOS Glob Public Health*. **2023 Aug 7**;3(8):e0002240. doi: 10.1371/journal.pgph.0002240. PMID: 37549128; PMCID: PMC10406184.
119. **Nakijoba R, Nakayiwa Kawuma A**, Ojara FW, Tabwenda JC, Kyeyune J, Turyahabwe C, **Asiimwe SP**, Magoola J, Banda CG, **Castelnovo B, Buzibye A, Waitt C**. *-Pharmacokinetics of antimalarial drugs used to treat uncomplicated malaria in breastfeeding mother-infant pairs: An observational pharmacokinetic study*. *Wellcome Open Res*. **2023 Aug 10**;8:12. doi: 10.12688/wellcomeopenres.18512.1. PMID: 37744730; PMCID: PMC10514676.
120. Ainembabazi P, **Castelnovo B, Okoboi S**, Arinaitwe WJ, Sebuyira LM, Parkes-Ratanshi R, Byakika-Kibwika P. *Building Capacity for Research Ethics Committees in Uganda*. *J Empir Res Hum Res Ethics*. **2023 Jul**;18(3):91-98. doi: 10.1177/15562646231177410. Epub 2023 Jun 4. PMID: 37272030; PMCID: PMC10330252.
121. Boulware DR, Atukunda M, Kagimu E, Musubire AK, Akampurira A, Tugume L, Ssebambulidde K, Kasibante J, Nsangi L, Mugabi T, Gakuru J, Kimuda S, Kasozi D, Namombwe S, Turyasingura I, Rutakingirwa MK, Mpoza E, Kigozi E, Muzoora C, Ellis J, Skipper CP, Matkovits T, Williamson PR, Williams DA, Fieberg A, Hullsiek KH, Abassi M, Dai B, **Meya DB**. *Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial*. *Clin Infect Dis*. **2023 Aug 22**:ciad440. doi: 10.1093/cid/ciad440. Epub ahead of print. PMID: 37606364. (No PDF)
122. Sekar P, Nalintya E, Kwizera R, Mukashyaka C, Niyonzima G, Namakula LO, Nerima P, Fieberg A, Dai B, Ellis J, Boulware DR, **Meya DB**, Bahr NC, Rajasingham R. *Prevalence of Histoplasma Antigenuria among Outpatient Cohort with Advanced HIV in Kampala, Uganda*. *J Fungi (Basel)*. **2023 Jul 18**;9(7):757. doi: 10.3390/jof9070757. PMID: 37504745; PMCID: PMC10381727.
123. Eric E, Olupot-Olupot P, Bwayo D, **Meya D**, Katuramu R. *Prevalence and Factors Associated With Cryptococcal Antigenemia Among Patients With Advanced Human Immunodeficiency Virus in Eastern Uganda: A Facility-Based Cross-sectional Study*. *Open Forum Infect Dis*. **2023 Jul 19**;10(7):ofad351. doi: 10.1093/ofid/ofad351. PMID: 37520409; PMCID: PMC10372861.
124. **Okurut S**, Boulware DR, Okafor E, Rhein J, Kajumbula H, Bagaya B, Bwanga F, Olobo JO, Manabe YC, Meya DB, Janoff EN; ASTRO trial team. *Divergent Neuroimmune Signatures in the Cerebrospinal Fluid Predict Differential Gender-Specific Survival Among Patients With HIV-Associated Cryptococcal Meningitis*. *medRxiv [Preprint]*. **2023 Aug 15**:2023.08.09.23293903. doi: 10.1101/2023.08.09.23293903. PMID: 37645984; PMCID: PMC10462187.
125. Link A, Okwir M, Iribarren S, **Meya D**, Bohjanen PR, Kasprzyk D. *Lack of education, knowledge, and supplies are barriers to cryptococcal meningitis care among nurses and other healthcare providers in rural Uganda: A mixed methods study*. *Nurse Educ Today*. **2023 Sep**;128:105873. doi: 10.1016/j.nedt.2023.105873. Epub 2023 Jun 14. PMID: 37390523. (No PDF)
126. **Bakiika H**, Obuku EA, **Bukirwa J, Nakiire L**, Robert A, Nabatanzi M, Robert M, Moses M, Achan MI, Kibanga JB, Nakanwagi A, Makumbi I, Nabukenya I, **Lamorde M**. *Contribution of the one health approach to strengthening health security in Uganda: a case study*. *BMC Public Health*. **2023 Aug 7**;23(1):1498. doi: 10.1186/s12889-023-15670-3. PMID: 37550671; PMCID: PMC10408150.
127. **Kakooza F**, Golparian D, Matoga M, Maseko V, Lamorde M, Krysiak R, Manabe YC, Chen JS, Kularatne R, Jacobsson S, Godreuil S, Hoffman I, Bercot B, Wi T, Unemo M. *Genomic surveillance and antimicrobial resistance determinants in Neisseria gonorrhoeae isolates from Uganda, Malawi and South Africa, 2015-20*. *J Antimicrob Chemother*. **2023 Aug 2**;78(8):1982-1991. doi: 10.1093/jac/dkad193. PMID: 37352017. (No PDF)

128. Pratt C, Kesande M, Tusabe F, Medley A, Prentice-Mott G, Lozier M, Trinies V, Yapswale S, Nabatyanga S, **Isabirye H**, **Lamorde M**, Berendes D. *Access to and Use of Hand Hygiene Resources during the COVID-19 Pandemic in Two Districts in Uganda, January-April 2021*. *Am J Trop Med Hyg.* **2023 Aug** 28;109(4):881-889. doi: 10.4269/ajtmh.23-0031. PMID: 37640292; PMCID: PMC10551090.
129. Jorgensen AL, Orrell C, **Waite C**, Toh CH, **Sekaggya-Wiltshire C**, Hughes DA, Allen E, Okello E, Tatz G, Culeddu G, Asiimwe IG, Semakula JR, Mouton JP, Cohen K, Blockman M, **Lamorde M**, Pirmohamed M. *A "Bundle of Care" to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study*. *JMIR Res Protoc.* **2023 Jul** 19;12:e46710. doi: 10.2196/46710. PMID: 37467034; PMCID: PMC10398551.(No PDF)
130. Zhou XD, Targher G, Byrne CD, Somers V, Kim SU, Chahal CAA, Wong VW, Cai J, Shapiro MD, Eslam M, Steg PG, Sung KC, Misra A, Li JJ, Brotons C, Huang Y, Papatheodoridis GV, Sun A, Yilmaz Y, Chan WK, Huang H, Méndez-Sánchez N, Alqahtani SA, Cortez-Pinto H, Lip GYH, de Knegt RJ, **Ocama P**, Romero-Gomez M, Fudim M, Sebastiani G, Son JW, Ryan JD, Ikonomidis I, Treeprasertsuk S, Pastori D, Lupsor-Platon M, Tilg H, Ghazinyan H, Boursier J, Hamaguchi M, Nguyen MH, Fan JG, Goh GB, Al Mahtab M, Hamid S, Perera N, George J, Zheng MH. *An international multidisciplinary consensus statement on MAFLD and the risk of CVD*. *Hepatol Int.* **2023 Aug**;17(4):773-791. doi: 10.1007/s12072-023-10543-8. Epub 2023 May 19. PMID: 37204656; PMCID: PMC10198034.
131. Matthews PC, **Ocama P**, Wang S, El-Sayed M, Turkova A, Ford D, Torimiro J, Garcia Ferreira AC, Miranda AE, De La Hoz Restrepo FP, Seremba E, Mbu R, Pan CQ, Razavi H, Dusheiko G, Spearman CW, Hamid S. *Reply to: "Does currently recommended maternal antiviral prophylaxis against mother-to-child transmission of hepatitis B virus require enhancement?"*. *JHEP Rep.* **2023 Aug** 7;5(11):100875. doi: 10.1016/j.jhepr.2023.100875. PMID: 37822785; PMCID: PMC10563044.
132. Yendewa GA, Sellu EJ, Kpaka RA, James PB, Yendewa SA, Cummings PE, Babawo LM, Massaquoi SP, Ghazawi M, **Ocama P**, Lakoh S, Babawo LS, Salata RA. *Measuring stigma associated with hepatitis B virus infection in Sierra Leone: Validation of an abridged Berger HIV stigma scale*. *J Viral Hepat.* **2023 Jul**;30(7):621-629. doi: 10.1111/jvh.13838. Epub 2023 Apr 21. PMID: 37084170; PMCID: PMC10330123.
133. Maureen Ayikoru, Cole J, Dodds K, Atcero M, Bada JK, Petrikova I, **Wordria W**. *Addressing vaccine concerns through the spectrum of vaccine acceptance*. *Soc Sci Med.* **2023 Sep**;333:116146. doi: 10.1016/j.socscimed.2023.116146. Epub 2023 Aug 7. PMID: 37579556.(No PDF)
134. Abelman RA, Fitzpatrick J, Zawedde J, Sanyu I, Byanyima P, Kaswabuli S, Musisi E, Hsieh J, Gardner K, Zhang M, Byanova KL, Sessolo A, Hunt PW, Lalitha R, Davis JL, Crothers K, **Wordria W**, Huang L. *Sex modifies the risk of HIV-associated obstructive lung disease in Ugandans postpneumonia*. *AIDS.* **2023 Sep** 1;37(11):1683-1692. doi: 10.1097/QAD.0000000000003626. Epub 2023 Jun 19. PMID: 37352494; PMCID: PMC10527596.
135. Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L, Bukirwa A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nasuna I, Nyawere J, Visente D, Cook C, Nalugwa T, Bachman CM, Semitalia F, Weigl BH, Connelly J, **Wordria W**, Cattamanchi A. *New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics*. medRxiv [Preprint]. **2023 Aug** 15:2023.08.10.23293680. doi: 10.1101/2023.08.10.23293680. PMID: 37645869; PMCID: PMC10462213. (No PDF)
136. Kwizera A, Kabatooro D, Atumanya P, Tumukunde J, Kalungi J, Mwanje AK, Obua D, Agaba P, Sendagire C, Nakibuuka J, Owachi D, Dünser MW, Alenyo-Ngabirano A, Olaro C, Kyobe-Bosa H, Kirenga BJ, **Nakiyingi L**, Kiwanuka N, Kateete DP, Joloba M, Sewankambo N, Summers C. *Respiratory Support Techniques for COVID-19-Related ARDS in a Sub-Saharan African Country: A Multicenter Observational Study*. *Chest.* **2023 Aug**;164(2):369-380. doi: 10.1016/j.chest.2023.01.039. Epub 2023 Feb 10. PMID: 36773933; PMCID: PMC9911971.
137. Headcraph E, Atukunda I, Kaddumukasa M, **Nakiyingi L**, Lusobya RC, Ampaire-Musika A, Otiike C, Nagawa E, Juma P, Msonge F, Otiti-Sengeri J. *Spectrum of and Factors Associated with Eye Disorders among Rheumatoid Arthritis Patients Attending Tertiary Hospital in Uganda*. *Open Access Rheumatol.* **2023 Jul** 13;15:103-111. doi: 10.2147/OARRR.S413697. PMID: 37465162; PMCID: PMC10351586.

138. Adrawa N, Ongiro S, Lotee K, Seret J, Adeke M, **Izudi J**. *Use of a context-specific package to increase sputum smear monitoring among people with pulmonary tuberculosis in Uganda: a quality improvement study*. *BMJ Open Qual*. **2023 Aug**;12(3):e002314. doi: 10.1136/bmjopen-2023-002314. PMID: 37558284; PMCID: PMC10414073.
139. Omam LA, Jarman E, O’Laughlin KN, **Parkes-Ratanshi R**. *Primary healthcare delivery models in African conflict-affected settings: a systematic review*. *Confl Health*. **2023 Jul 15**;17(1):34. doi: 10.1186/s13031-023-00533-w. PMID: 37454133; PMCID: PMC10349495.
140. Beck EJ, Laeyendecker O, Saraf S, Ashokkumar S, Onzia A, Melendez JH, Chan J, Kyambadde P, Gough E, **Parkes-Ratanshi R**, Manabe YC, Hamill MM. *High level of HIV viral suppression in a cross-sectional study of Ugandan men with urethritis and bacterial STI*. *Int J STD AIDS*. **2023 Aug 6**:9564624231193491. doi: 10.1177/09564624231193491. Epub ahead of print. PMID: 37544771. **(No PDF)**
141. Klabbers RE, Muwonge TR, Ajidiru S, Borthakur S, Mujugira A, Sharma M, Vinck P, Pham P, Celum C, **Parkes-Ratanshi R**, O’Laughlin KN. *Understanding the barriers and facilitators of COVID-19 risk mitigation strategy adoption and COVID-19 vaccination in refugee settlements in Uganda: a qualitative study*. *BMC Public Health*. **2023 Jul 20**;23(1):1401. doi: 10.1186/s12889-023-16320-4. PMID: 37474936; PMCID: PMC10360310.
142. Najjemba L, Kawuma AN, Ojara FW, Obura B, **Sekaggya-Wiltshire C**, Arinaitwe W, Kikonyogo R, Mukonzo J, Pillai GC, Waitt C. *A commentary on establishing a local centre of excellence for research and training in pharmacometrics: Lessons from the pharmacometrics Africa-Uganda chapter*. *Br J Clin Pharmacol*. **2023 Sep**;89(9):2658-2661. doi: 10.1111/bcp.15832. Epub 2023 Jul 7. PMID: 37417585.
143. Natukunda B, Omoding A, Bongomin F, Mubiru KR, Ddungu H, **Sekaggya-Wiltshire C**, Mayanja-Kizza H. *One-Year Survival and Prognosticators of Adults With Acute Leukemia at the Uganda Cancer Institute*. *JCO Glob Oncol*. **2023 Jul**;9:e2200244. doi: 10.1200/GO.22.00244. PMID: 37499182; PMCID: PMC10581653.
144. **Mujugira A**, Nakyanzi A, Donnell D, Boyer J, Stein G, Bulterys M, Naddunga F, Kyomugisha J, Birungi JE, Ssendiwala P, Nsubuga R, Muwonge TR, Musinguzi J, Sharma M, Celum CL. *Partner testing with HIV self-test distribution by Ugandan pregnant women living with HIV: a randomized trial*. *J Int AIDS Soc*. **2023 Sep**;26(9):e26156. doi: 10.1002/jia2.26156. PMID: 37675834; PMCID: PMC10483500.
145. Njovu IK, Nalumaga PP, Ampaire L, Nuwagira E, Mwesigye J, Musinguzi B, Kassaza K, Taseera K, Kiguli Mukasa J, Bazira J, Iramiot JS, Baguma A, Bongomin F, **Kwizera R**, Achan B, Cox MJ, King JS, May R, Ballou ER, Itabangi H. *Investigating Metabolic and Molecular Ecological Evolution of Opportunistic Pulmonary Fungal Coinfections: Protocol for a Laboratory-Based Cross-Sectional Study*. *JMIR Res Protoc*. **2023 Aug 15**;12:e48014. doi: 10.2196/48014. PMID: 37581914; PMCID: PMC10466149.
146. Kibone W, Semulimi AW, **Kwizera R**, Bongomin F. *Improving mycetoma case detection through the training of community health workers in Northern Uganda: protocol for a stepped-wedge cluster-randomized trial*. *Ther Adv Infect Dis*. **2023 Sep 8**;10:20499361231198332. doi: 10.1177/20499361231198332. PMID: 37693860; PMCID: PMC10492465.
147. Jung L, Kiwanuka J, Mbabazi L, Nakate V, **Musaazi J**, Nabajja H, Kajumbula H, Lübbert C, Mwaka E, Nsibirwa S, von Braun A. *A case for routine microbial diagnostics: Results from antimicrobial susceptibility testing in post-traumatic wound infections at a Ugandan tertiary care hospital*. *PLOS Glob Public Health*. **2023 Aug 15**;3(8):e0001880. doi: 10.1371/journal.pgph.0001880. PMID: 37582103; PMCID: PMC10427013.

148. **Naggirinya AB**, Nuwamanya E, Nabaggala MS, Musinguzi F, Nanungi A, Waiswa P, Rujumba J, Meya DB, Parkes-Ratanshi R. *Cost-effectiveness of an interactive voice response system for improving retention in care and adherence to antiretroviral therapy among young adults in Uganda.* BMC Digital Health. **2024 Sep 20**;2(1):65.
149. Kibirige D, Sekitoleko I, **Owarwo N**, Andia-Biraro I, Lumu W. *HIV infection in adult Ugandans with new-onset type 2 diabetes: exploring its influence on the anthropometric and metabolic profile.* AIDS Res Ther. **2023 Aug 18**;20(1):56. doi: 10.1186/s12981-023-00553-9. PMID: 37596620; PMCID: PMC10439581.

